Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Neurogene Inc has a consensus price target of $49 based on the ratings of 6 analysts. The high is $65 issued by BMO Capital on June 27, 2024. The low is $31 issued by Stifel on January 5, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BMO Capital, and HC Wainwright & Co. on August 12, 2024, June 27, 2024, and June 20, 2024, respectively. With an average price target of $55 between HC Wainwright & Co., BMO Capital, and HC Wainwright & Co., there's an implied 37.71% upside for Neurogene Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Neurogene (NASDAQ:NGNE) was reported by HC Wainwright & Co. on August 12, 2024. The analyst firm set a price target for $49.00 expecting NGNE to rise to within 12 months (a possible 22.68% upside). 15 analyst firms have reported ratings in the last year.
The latest analyst rating for Neurogene (NASDAQ:NGNE) was provided by HC Wainwright & Co., and Neurogene maintained their buy rating.
There is no last upgrade for Neurogene
There is no last downgrade for Neurogene.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Neurogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Neurogene was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.
While ratings are subjective and will change, the latest Neurogene (NGNE) rating was a maintained with a price target of $51.00 to $49.00. The current price Neurogene (NGNE) is trading at is $39.94, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.